News
Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
In this week’s edition of InnovationRx, we look at Immuneering’s slow-and-steady approach to cancer fighting, litigation over ...
Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...
President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...
Merck announces plans of buying Verona for a huge premium. VRNA deal could shield Merck from two major headwinds.
Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback